A number of investment brokers have recently updated their price targets on shares of Actinium Pharmaceuticals, Inc. (ATNM). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

02/29/2016 – H.C. Wainwright began new coverage on Actinium Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 8 price target on the stock.

11/30/2015 – Actinium Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 12 price target on the stock.

01/14/2015 – MLV & Co began new coverage on Actinium Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 15 price target on the stock.

07/22/2014 – Canaccord Genuity began new coverage on Actinium Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 16 price target on the stock.

The share price of Actinium Pharmaceuticals, Inc. (ATNM) was down -2.82% during the last day of trading, with a day high of 1.76. 301960 shares were traded during the last session.

The stock’s 50 day moving average is 1.97 and its 200 day moving average is 2.12. The stock’s market capitalization is 72.27M. Actinium Pharmaceuticals, Inc. has a 52-week low of 1.52 and a 52-week high of 4.34.

View other investors thoughts on Actinium Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.